Liminatus Pharma Inc. has announced a strategic partnership through a Memorandum of Understanding to form a research and development consortium with Samda Biolab Co., Ltd. and INNOCS AI. This collaboration aims to advance a novel blood-based diagnostic kit for early detection of pancreatic cancer. Leveraging INNOCS AI's artificial intelligence technology and Samda's biomarker platform, alongside Liminatus Pharma's regulatory and commercial expertise, the partnership seeks to enhance corporate value and establish a strong foothold in the precision oncology diagnostics market. This initiative is seen as a critical milestone towards transforming cancer care and is expected to position Liminatus Pharma as a leader in metabolomics-driven cancer diagnostics. The consortium's innovative approach has demonstrated high sensitivity and specificity in recent clinical data, underscoring its potential impact on the global pancreatic cancer diagnostics market.